BioMedNewsBreaks

ThursdaySep 17, 2026 11:31 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and a $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report. To view the full press release, visit https://ibn.fm/WNsHM About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

Continue Reading

ThursdaySep 17, 2026 11:22 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project 

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique - Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker. DETECSEPS will evaluate an early detection approach combining a routinely used clinical score with Volition’s Nu.Q NETs H3.1 blood…

Continue Reading

ThursdaySep 17, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings more than 30 years of international experience spanning investment banking, corporate finance, asset management and capital markets. His appointment comes as VERAXA advances its proprietary BiTAC platform and a pipeline centered on antibody-drug conjugates and T-cell engagers. VERAXA has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, adding a finance executive with more than three decades of…

Continue Reading

ThursdaySep 17, 2026 9:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTCQB: ETST) Uplists to OTCQB Venture Market

Earth Science Tech (OTCQB: ETST), a holding company with a diversified portfolio of distinct entities, announced its successful uplisting to the OTCQB Venture Market, effective for trading Sept. 17, 2026. The OTCQB requires companies to meet financial and reporting standards, undergo annual verification and comply with management certification requirements. To view the full press release, visit https://ibn.fm/oYq2M About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms,…

Continue Reading

WednesdaySep 16, 2026 3:43 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach

VERAXA Biotech (NASDAQ: VRXA) is developing an oncology pipeline centered on engineered antibody therapies, with a particular focus on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting “AND-gated” approach intended to activate therapeutic effects preferentially when two tumor-associated targets are present on the same cancer cell, potentially addressing the challenge of on-target, off-tumor toxicity. The company has reported early laboratory data supporting the concept in both TCE and ADC applications, while its lead BiTAC-TCE has advanced into cell-line development and planned IND/CTA-enabling work following regulatory feedback from Germany’s Paul-Ehrlich-Institute. Separately, VERAXA’s VXA-222 bispecific…

Continue Reading

WednesdaySep 16, 2026 3:22 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Targets Greater Scale Following Q1 Growth

Earth Science Tech (OTC: ETST) recently reported Q1 2027 results that management says demonstrate continued progress from its strategy of acquiring and scaling profitable healthcare, pharmaceutical, and telemedicine businesses. For the quarter ended June 30, 2026, revenue rose 3% to $9.0 million, gross profit increased 3.1% to $6.3 million, net income climbed 57% to $715,697, operating cash flow more than doubled to $707,131, and total assets grew 33.3% to $10.4 million compared with Q1 2026. Looking ahead, ETST plans to expand geographically, develop its telehealth and pharmacy fulfillment platforms, improve operating efficiency, and pursue greater institutional investor participation. To view…

Continue Reading

WednesdaySep 16, 2026 11:00 am

BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters and healthcare workers. Participants will receive Optimi’s synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in…

Continue Reading

TuesdaySep 15, 2026 12:29 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. Quantum BioPharma recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing the company to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS. To…

Continue Reading

MondaySep 14, 2026 1:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) was featured in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlighting FDA clearance of the company’s Investigational New Drug (“IND”) application for Lucid-MS. According to the company, the approximately 15,000-page IND submission included a comprehensive package of pharmacology, toxicology and manufacturing data, with the clearance allowing Quantum BioPharma to move directly into a randomized, double-blind, placebo-controlled Phase 2 trial evaluating Lucid-MS in people with multiple sclerosis. Lucid-MS is the company’s patented…

Continue Reading

FridaySep 11, 2026 11:31 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial 

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC(R) U.S. trial and now expects to complete enrollment around year-end. Regentis also expanded its U.S. and European clinical networks, advanced preparations for European commercialization and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared…

Continue Reading